Michelle Boxall, CEO of IB Communications, is thrilled to be part of Advanced therapies think tank, alongside industry leaders and co founders Lee Buckler and Sven Kili, and as host and panelist Audrey Greenberg. The launch of AT3 at Advanced Therapies Week 2025 marks an exciting new initiative designed to tackle the most pressing challenges in the rapidly evolving advanced therapies field.
What is AT3?
AT3 is a dynamic platform aimed at fostering open, respectful, and thought-provoking dialogue on the key issues shaping the future of advanced therapies. Founded by Lee Buckler, Sven Kili and Michelle, AT3 provides a unique space for researchers, entrepreneurs, regulators, and patient advocates to engage in constructive debates about the ethical, regulatory, and access challenges facing the industry.
In a field marked by rapid innovation and complex challenges, differing perspectives often lead to friction. AT3 embraces these differences, creating an environment where tough questions are tackled head-on, and bold ideas can be shared. From ethical concerns to pricing models and patient access, no topic is off-limits.
A Platform for Constructive Debate
For Michelle, this inclusive approach is one of the most exciting aspects of AT3. "We’re in an industry that’s advancing at lightning speed, but that comes with complexities,” she says. “AT3 offers a space to address those complexities—whether it’s gene editing, pricing, or ensuring equitable access to therapies."
AT3’s strength lies in its commitment to diverse voices. The platform seeks to challenge conventional thinking, propose actionable solutions, and spark innovative ideas through rigorous discussion. Whether you're a scientist, entrepreneur, policymaker, or patient advocate, AT3 invites everyone to join the conversation and help shape the future of advanced therapies.
Tackling the Tough Questions
At AT3, no issue is too difficult to address. The platform will explore critical topics such as:
Regulatory hurdles that delay access to therapies.
Pricing and reimbursement models that create barriers to affordability.
Ethical concerns around gene therapies and cell-based treatments.
Ensuring equitable access to treatments for underserved populations.
Michelle believes that engaging openly on these topics is key to driving the industry forward. “We need to bring people together to address these issues, challenge assumptions, and come up with real solutions that move us closer to better patient outcomes.”
A Vision for the Future
Launching at Phacilitate’s Advanced Therapies Week 2025, AT3 aims to be a catalyst for meaningful change in the advanced therapies sector. Through panel discussions, roundtables, and collaborative events, AT3 will spark the conversations that will define the future of this transformative field.
“We’re at a pivotal moment in advanced therapies,” Michelle says. “But to unlock their full potential, we need to engage in honest, bold conversations. AT3 is that space.”
Join the Conversation
AT3 invites everyone with a stake in the future of advanced therapies—researchers, entrepreneurs, policymakers, investors, and patients—to join the conversation. By bringing together diverse perspectives and encouraging constructive debate, AT3 hopes to drive progress and unlock the full potential of cutting-edge treatments.
As Michelle, Lee, Sven, and Audrey work together to lead this initiative, the future of advanced therapies looks brighter than ever. AT3 is poised to be a driving force in shaping the industry and sparking the discussions that will lead to better solutions for patients worldwide.
Stay tuned for more updates on AT3, and join us in shaping the next chapter of advanced therapies.
Comments